Skip to main content
TipRanks
Go Ultimate75% OFF

Aspen Pharmacare Holdings (LDZA) Q4 2026 Earnings Report

0 Followers

DE:LDZA Q4 2026 EPS Results

Actual EPS
EUR 0.14
Consensus EPS
―
Beat/Miss
―
One Year Ago EPS
-EUR 0.38

DE:LDZA Q4 2026 Revenue Results

Actual Revenue
EUR 962.84M
Expected Revenue
―
Beat/Miss
―
YoY Revenue Growth
-6.87%

Earnings Announcement Details

Quarter
Q4 2026
Date
09/02/2026
Time
Before Open
Conference Call
Wednesday, September 2, 2026
DE:LDZA Upcoming Earnings

Aspen Pharmacare Holdings's next earnings date is estimated for March 11, 2027, based on past reporting schedules.

Q4 2026 Earnings Call Audio

DE:LDZA Q4 2026 Earnings Call
0:00 / 0:00

Q4 2026 Earnings Slide Deck

Q4 2026 Earnings Call Summary

Q4 2026
Earnings Call Date:Sep 02, 2026|% Change Since:17.96%|
Earnings Call Sentiment|Positive

The call was strongly optimistic. Aspen reported substantial EBITDA, normalized earnings, margin, cash flow, and balance-sheet improvements despite flat group revenue, the loss of a major manufacturing contract, geopolitical impacts, restructuring charges, and a Canadian GLP-1 API issue. Management raised sterile manufacturing guidance and provided expectations for more than 50% normalized headline earnings growth in financial year 2027.

Company Guidance

For financial year '27, Aspen expects to sustain organic growth led by emerging markets, with its base business growing in mid-single digits, both in revenue and EBITDA; manufacturing revenue growth of greater than 50%, manufacturing EBITDA more than double financial year '26 EBITDA, and sterile finished dose form revenue growth of 50% with positive EBITDA, supported by a steriles EBITDA target raised from ZAR 1.7 billion to ZAR 2.2 billion. The company expects at least ZAR 9 billion of EBITDA, substantial double-digit growth in NHEPS of more than 50%, stronger free cash flow, tax rates of 24%, 25%, Mounjaro sales of more than ZAR 2 billion, and commencement of GLP-1s to be additive; heparin turnover is expected to decrease, substantial decrease, while EBITDA doesn't change, and APIs are expected to contribute to growth in financial year '27.

  • Commercial Pharma EBITDA GrowthCommercial pharma delivered 13% EBITDA growth at constant exchange rates, extending double-digit growth achieved in financial year 2025. Revenue grew 5%, or 7% excluding China, supported by organic growth in emerging markets.
  • Manufacturing EBITDA RecoveryManufacturing EBITDA increased 21% at constant exchange rates, from ZAR 647 million to ZAR 828 million, despite the loss of a ZAR 1 billion mRNA contract. The sterile finished-dose-form reshape program generated ZAR 1.2 billion of EBITDA improvement, more than offsetting the contract loss.
  • Strong Earnings LeverageGroup revenue was flat at constant exchange rates, while gross profit increased 4%, normalized EBITDA grew 14% to ZAR 7.7 billion, and normalized headline earnings per share increased 28% to ZAR 8.02.
  • Improved Gross Margin and Operating EfficiencyGross profit margin increased from 41.6% to 43%, while operating expenses declined 4% and fell to just under 25% of revenue from 26% in the prior year. Management attributed the improvement to reshape benefits and operational efficiencies.
  • Record Free Cash Flow GenerationFree cash flow reached ZAR 3.8 billion, compared with almost breakeven in the prior year and ZAR 700 million two years earlier. Cash generated from operating activities increased to ZAR 6.8 billion from ZAR 5 billion, while capital expenditure declined to ZAR 3 billion from ZAR 5 billion.
  • Stronger Balance Sheet and Share BuybacksAspen ended the year with net cash of ZAR 0.8 billion after ZAR 0.5 billion of share buybacks. The company subsequently increased its share buyback program to ZAR 2 billion, equivalent to 3% of the company.
  • APAC Value UnlockThe APAC divestment generated ZAR 28 billion of gross proceeds and a profit on sale of ZAR 2.4 billion. Management described the transaction as an indicator of the underlying asset value of Aspen's sum of parts at an 11.5x EBITDA multiple.
  • Positive FY2027 Earnings GuidanceManagement guided to normalized EBITDA of at least ZAR 9 billion in financial year 2027, implying more than ZAR 1.3 billion of growth from the ZAR 7.7 billion achieved in financial year 2026. Normalized headline earnings per share is expected to grow by more than 50%, with interest savings of more than ZAR 1.2 billion.
  • Sterile Manufacturing Guidance RaisedSterile manufacturing EBITDA guidance for financial year 2027 was raised from ZAR 1.7 billion to ZAR 2.2 billion, supported by growing volumes, growing revenue, reduced costs, and annualized benefits from restructuring and efficiency programs.
  • Manufacturing Revenue Growth OutlookManagement forecast manufacturing revenue growth of greater than 50% in financial year 2027. Sterile finished-dose-form revenue is forecast to grow by 50%, with revenue growth expected in both South Africa and France.
  • Mounjaro and GLP-1 MomentumThe South African GLP-1 market nearly doubled to ZAR 2.8 billion, while Mounjaro's share increased from 15% to 53% over the last 12 months. Mounjaro accounted for 40% of growth in the South African private pharmaceutical market, and management expects more than ZAR 2 billion of Mounjaro sales in financial year 2027.
  • GLP-1 Global Rollout ProgressAspen has two generic GLP-1 products registered in Canada, has submitted products in multiple emerging markets, and believes its Brazil dossier is advancing. Sub-Saharan Africa registration processes have commenced, with submissions in Kenya and Nigeria potentially contributing in financial year 2027.
  • Heparin Process ImprovementsNew streamlined heparin processes have reduced sourcing costs and inventory levels in both value and volume. Management expects heparin turnover to decrease substantially while EBITDA remains unchanged because sourcing costs are linked to the commodity price.
  • API Business Returning to GrowthThe API business returned to growth, driven by improved supply of human chorionic gonadotropin, a fertility product, and new product launches.
  • Insulin and Vaccine Manufacturing ProgressThe commercialization of the insulin contract in South Africa was identified as an important manufacturing landmark. The WHO completed its inspection of Aspen's site for pediatric HEXA and PCV vaccines, and management hopes to receive WHO prequalification in the current calendar year.
  • Expanded HIV Treatment and Prevention OpportunitiesAspen received FDA approval for its site to manufacture a triple-dose ARV, enabling it to pursue broader African volumes and donor-funded markets. The company also entered into a license with Merck for a once-monthly oral HIV prevention tablet currently in Phase III clinical trials.
  • Patient Access and Sustainability ProgressAspen reported reaching more than 165 million patients in emerging markets with critical and essential medicines. Women represented 32% of top leadership positions, up from 19% in 2020; more than 2,000 suppliers were screened under the responsible supply chain program; Scope 1 and 2 carbon emissions were reduced by 34% versus the FY2020 base year; and renewable energy usage increased to 26% from 19%.
  • Capital Allocation PrioritiesManagement said its preferred use of capital is share buybacks, while also prioritizing organic growth, retaining the dividend payout, maintaining disciplined capital allocation, and continuing to assess sum-of-parts value-unlock opportunities. No large-scale acquisitions are planned, although bolt-on product ranges may be considered.

DE:LDZA Earnings History

DE:LDZA earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 11, 20272027 (Q2)―-0.17――
Sep 02, 20262026 (Q4)―0.14-0.38137.88% (+0.52)
Mar 03, 20262026 (Q2)―0.170.27-36.67% (-0.10)
Sep 03, 20252025 (Q4)―-0.380.22-269.32% (-0.60)
Mar 03, 20252025 (Q2)―0.270.257.91% (+0.02)
Oct 02, 20242024 (Q4)―0.220.28-20.32% (-0.06)
Mar 04, 20242024 (Q2)―0.250.31-20.11% (-0.06)
Aug 30, 20232023 (Q4)―0.280.4-30.00% (-0.12)
Mar 01, 20232023 (Q2)―0.310.44-28.98% (-0.13)
Aug 31, 20222022 (Q4)―0.400.2938.04% (+0.11)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed